WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, which will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Contact
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…
Transaction could raise up to $1 billion in aggregate gross proceeds if all of the…
PLEASANTON, Calif., Aug. 28, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that,…
LONG BEACH, Calif., Aug. 28, 2025 /PRNewswire/ -- In a groundbreaking jury trial that marks…
NEWTOWN, Pa., Aug. 28, 2025 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP, based…
PARAMUS, N.J., Aug. 28, 2025 /PRNewswire/ -- Providers who use the ONC and ASAM-certified MedicsCloud…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
